Vaccinations Should Continue As Influenza Pandemics Epidemics Wane
According to Predictive Computer Model Study in American Journal of Preventive Medicine
San Diego, CA, 5 October, 2010 – Influenza pandemics often come in multiple waves. As the one wave subsides, public health officials have to decide whether continuing vaccination programs is warranted to prevent or reduce a subsequent wave. In a new study published in the November issue of the American Journal of Preventive Medicine, researchers report on a new computer model that can be used to predict both subsequent-wave mechanisms and vaccination effectiveness. They conclude that additional waves in an epidemic can be mitigated by vaccination even when an epidemic appears to be waning.
As part of ongoing work with the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services during the H1N1 influenza pandemic, the University of Pittsburgh Models of Infectious Disease Agent Study (MIDAS) team employed an agent-based computer simulation model of the Washington, DC metropolitan region to delineate what mechanisms could generate a subsequent (e.g., “third) epidemic wave” and explored whether vaccinating the population at different rates and times would mitigate the wave. This model included explicit representations of the region’s individuals, school systems, workplaces/commutes, households, and communities.
“The present study identified potential mechanisms for a multiple-wave influenza epidemic and demonstrated how vaccination can mitigate additional waves, thereby supporting the continuation of a vaccination program even when an epidemic appears to be waning, as in December 2009 –January 2010,” commented lead investigator Bruce Y. Lee, MD, MBA, University of Pittsburgh School of Medicine and Graduate School of Public Health. “Although vaccinating a population before an epidemic begins is ideal, public health decision makers should not rule out initiating a vaccination program even though they know that the vaccine will not arrive in time to affect the initial wave of an epidemic. Uncertainties remained for decision making by public health officials on the question of dedicating resources and credibility to the H1N1 vaccination program. However, these simulations do lend support for continuation of the program and to continued public education on the benefits of receiving the vaccine.”
Four mechanisms have been identified that could cause a subsequent (e.g., third) epidemic wave: substantially increased viral transmissibility that changes with the seasons; progressive viral adaptation; an immune escape variant; and changes in social mixing from holiday school closures. These mechanisms were modeled using the Washington, DC metropolitan region and 7.4 million “agents” or virtual persons who carried out normal daily behaviors.
The model was calibrated to produce infection rates that mirrored historical outbreaks. Then, by implementing vaccinations, the researchers could examine the conditions where the third wave could be significantly mitigated. Scenarios showed that initiating vaccination earlier, increasing the speed of vaccination, and prioritizing population subgroups based on Advisory Committee on Immunization Practices (ACIP) recommendations; all had positive effects on the third wave.
The article is “Vaccination Deep Into a Pandemic Wave: Potential Mechanisms for a ‘Third Wave’ and the Impact of Vaccination” by Bruce Y. Lee, MD, MBA, Shawn T. Brown, PhD, Philip Cooley, MS, John J. Grefenstette, PhD, Richard K. Zimmerman, MD, MPH, Shanta M. Zimmer, MD, Margaret A. Potter, JD, MS, Roni Rosenfeld, PhD, William D. Wheaton, MA, Ann E. Wiringa, MPH, Kristina M. Bacon, MPH, and Donald S. Burke, MD, PhD. It appears in the American Journal of Preventive Medicine, Volume 39, Issue 5 (November 2010) published by Elsevier. doi: 10.1016/j.amepre.2010.07.014
# # #
Notes for Editors
Full text of the article is available to journalists upon request; contact eAJPM@ucsd.edu. To schedule an interview with the authors please contact Clare Collins, Manager, Media Relations, University of Pittsburgh Graduate School of Public Health, Tel: +1 412-648-9725, email@example.com.
About The American Journal of Preventive Medicine
The American Journal of Preventive Medicine (www.ajpm-online.net) is the official journal of The American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials.
The American Journal of Preventive Medicine, with an Impact Factor of 4.235, is ranked 11th out of 122 Public, Environmental & Occupational Health titles and 16th out of 132 General and Internal Medicine titles according to the 2010 Journal Citation Reports© published by Thomson Reuters.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
AJPM Editorial Office